• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管风险在多发性硬化症诊断后的轨迹和管理:1987 年至 2018 年在英格兰进行的基于人群的匹配队列研究。

Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England.

机构信息

Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK.

Department of Public Health, University of Naples Federico II, Naples, Italy.

出版信息

Mult Scler. 2024 Nov;30(13):1653-1663. doi: 10.1177/13524585241287388. Epub 2024 Oct 17.

DOI:10.1177/13524585241287388
PMID:39420581
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11568649/
Abstract

BACKGROUND

People with multiple sclerosis (PwMS) have an increased cardiovascular and cerebrovascular disease burden, but this could be mitigated by vascular risk factor management.

OBJECTIVES

We compared the trajectories of vascular risk factors, vascular comorbidities and clinical management in PwMS against the general population post-MS diagnosis while controlling for frailty.

METHODS

Retrospective longitudinal analysis using English data from the Clinical Practice Research Datalink between 1987 and 2018 comprising PwMS matched with up to six controls without MS by age, sex and general practice.

RESULTS

We compared 12,251 PwMS with 72,572 matched controls; 3.8% of PwMS had mild-moderate frailty, 1.2% more than matched controls. Compared to controls, PwMS had an elevated incidence of Type 2 diabetes (HR 1.18, 95% CI (1.04, 1.34)), and starting antihypertensive medications (HR 1.40, 95% CI (1.33, 1.47)). Among those with hypertension at baseline, blood pressure trajectories did not differ between PwMS and controls. PwMS had increased rates of meeting targets for hypertension management (HR 1.25, 95% CI (1.12, 1.41)).

CONCLUSION

The observation that PwMS with hypertension are more likely to meet treatment targets than matched controls is encouraging, but the elevated rates of vascular comorbidities suggest that tighter vascular management may be needed in this population.

摘要

背景

多发性硬化症患者(PwMS)心血管和脑血管疾病负担增加,但通过管理血管危险因素可减轻这种负担。

目的

本研究旨在对比多发性硬化症患者与一般人群在多发性硬化症诊断后血管危险因素、血管合并症和临床管理的轨迹,同时控制衰弱情况。

方法

这是一项使用临床实践研究数据链接(1987 年至 2018 年)中的英国数据进行的回顾性纵向分析,纳入了 12251 例多发性硬化症患者和 72572 名匹配对照者,按年龄、性别和全科医生进行匹配。

结果

我们将 12251 例多发性硬化症患者与 72572 名匹配对照者进行了比较;3.8%的多发性硬化症患者存在轻度至中度衰弱,比匹配对照者多 1.2%。与对照者相比,多发性硬化症患者的 2 型糖尿病发生率更高(HR 1.18,95%CI(1.04,1.34)),且开始使用抗高血压药物的比例更高(HR 1.40,95%CI(1.33,1.47))。在基线时患有高血压的患者中,多发性硬化症患者和对照者的血压轨迹没有差异。多发性硬化症患者达到高血压管理目标的比例更高(HR 1.25,95%CI(1.12,1.41))。

结论

尽管多发性硬化症患者高血压的发生率更高,但观察到他们更有可能达到治疗目标,这令人鼓舞,但血管合并症的发生率较高表明该人群可能需要更严格的血管管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba43/11568649/19a912fca1fc/10.1177_13524585241287388-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba43/11568649/891ffa26c3c5/10.1177_13524585241287388-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba43/11568649/19a912fca1fc/10.1177_13524585241287388-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba43/11568649/891ffa26c3c5/10.1177_13524585241287388-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba43/11568649/19a912fca1fc/10.1177_13524585241287388-fig2.jpg

相似文献

1
Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England.血管风险在多发性硬化症诊断后的轨迹和管理:1987 年至 2018 年在英格兰进行的基于人群的匹配队列研究。
Mult Scler. 2024 Nov;30(13):1653-1663. doi: 10.1177/13524585241287388. Epub 2024 Oct 17.
2
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study.在英国,对多发性硬化症患者进行诊断时的血管风险管理:一项基于人群的研究。
Mult Scler. 2023 May;29(6):671-679. doi: 10.1177/13524585231164296. Epub 2023 Apr 7.
3
Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England.评估英格兰多发性硬化症患者发生大血管事件和死亡的风险。
JAMA Neurol. 2020 Jul 1;77(7):820-828. doi: 10.1001/jamaneurol.2020.0664.
4
Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.多发性硬化症患者的癌症风险:一项为期 10 年的全国回顾性队列研究。
Neurology. 2024 Nov 12;103(9):e209885. doi: 10.1212/WNL.0000000000209885. Epub 2024 Oct 9.
5
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.多发性硬化症患者感染 COVID-19 的风险:一项病例对照研究。
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2). doi: 10.1212/NXI.0000000000001141. Print 2022 Mar.
6
Prevalence of chronic comorbidities in people with multiple sclerosis: descriptive study based on administrative data in Tuscany (Central Italy).多发性硬化症患者慢性共病的患病率:基于意大利托斯卡纳(中部)行政数据的描述性研究。
Neurol Sci. 2022 Nov;43(11):6407-6414. doi: 10.1007/s10072-022-06345-9. Epub 2022 Aug 18.
7
Comorbid onset of cardiovascular diagnosis and long-term confirmed disability progression in multiple sclerosis: A 15-year follow-up study.多发性硬化症中心血管诊断与长期确诊残疾进展的共病发作:一项为期 15 年的随访研究。
J Neurol Sci. 2024 Sep 15;464:123156. doi: 10.1016/j.jns.2024.123156. Epub 2024 Jul 29.
8
Comparing the risk of serious infections in patients with and without MS: A German claims data analysis.比较患有和未患有多发性硬化症的患者发生严重感染的风险:一项德国索赔数据分析。
Mult Scler Relat Disord. 2023 Apr;72:104583. doi: 10.1016/j.msard.2023.104583. Epub 2023 Feb 21.
9
Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus: A Population-Based Cohort Study Assessing Sex Disparities.2 型糖尿病患者的心血管风险和危险因素管理:一项基于人群的队列研究,评估性别差异。
Circulation. 2019 Jun 11;139(24):2742-2753. doi: 10.1161/CIRCULATIONAHA.118.039100. Epub 2019 Apr 15.
10
Vascular disease risk factors in multiple sclerosis: Effect on metabolism and brain volumes.多发性硬化症的血管疾病危险因素:对代谢和脑容量的影响。
Mult Scler Relat Disord. 2023 Jun;74:104675. doi: 10.1016/j.msard.2023.104675. Epub 2023 Mar 31.

本文引用的文献

1
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study.在英国,对多发性硬化症患者进行诊断时的血管风险管理:一项基于人群的研究。
Mult Scler. 2023 May;29(6):671-679. doi: 10.1177/13524585231164296. Epub 2023 Apr 7.
2
Frailty and risk of microvascular complications in patients with type 2 diabetes: a population-based cohort study.2 型糖尿病患者衰弱与微血管并发症风险:基于人群的队列研究。
BMC Med. 2022 Dec 8;20(1):473. doi: 10.1186/s12916-022-02675-9.
3
An analysis of frailty and multimorbidity in 20,566 UK Biobank participants with type 2 diabetes.
对20566名患有2型糖尿病的英国生物银行参与者的虚弱和多病共存情况的分析。
Commun Med (Lond). 2021 Aug 27;1:28. doi: 10.1038/s43856-021-00029-9. eCollection 2021.
4
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy).多发性硬化症的急诊医疗:坎帕尼亚大区(意大利南部)的一项为期五年的人群研究。
Mult Scler. 2022 Apr;28(4):597-607. doi: 10.1177/13524585221074010.
5
Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.多发性硬化症、抑郁、血管疾病和死亡率的关系:一项基于人群的匹配队列研究。
Neurology. 2021 Sep 28;97(13):e1322-e1333. doi: 10.1212/WNL.0000000000012610. Epub 2021 Sep 1.
6
Hypertension and hypertension severity in Hispanics/Latinx with MS.西班牙裔/拉丁裔多发性硬化症患者的高血压和高血压严重程度。
Mult Scler. 2021 Oct;27(12):1894-1901. doi: 10.1177/13524585211019243. Epub 2021 Jul 1.
7
Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.多发性硬化症患者衰弱指数的操作性定义:一项横断面研究。
Mult Scler. 2021 Oct;27(12):1939-1947. doi: 10.1177/1352458520987541. Epub 2021 Feb 10.
8
Vascular disease and multiple sclerosis: a post-mortem study exploring their relationships.血管疾病与多发性硬化症:一项探索两者关系的尸检研究。
Brain. 2020 Oct 1;143(10):2998-3012. doi: 10.1093/brain/awaa255.
9
Frailty in ageing persons with multiple sclerosis.衰老多发性硬化症患者的虚弱。
Mult Scler. 2021 Apr;27(4):613-620. doi: 10.1177/1352458520923945. Epub 2020 May 27.
10
Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England.评估英格兰多发性硬化症患者发生大血管事件和死亡的风险。
JAMA Neurol. 2020 Jul 1;77(7):820-828. doi: 10.1001/jamaneurol.2020.0664.